The investigation of symptoms burden and treatment status in patients with bone metastasis
Objective This survey was a non-intervention study, which aimed to investigate symptom burden and treatment status in cancer patient with bone metastasis, and to make out whether patients received the normative treatment. Methods We designed a questionnaire, the main items of which include patient’s...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Shi, Zhiyong [verfasserIn] Qiu, Hong [verfasserIn] Yu, Shiying [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2010 |
|---|
| Übergeordnetes Werk: |
Enthalten in: The Chinese-german journal of clinical oncology - Berlin : Springer, 2002, 9(2010), 2 vom: Feb., Seite 63-67 |
|---|---|
| Übergeordnetes Werk: |
volume:9 ; year:2010 ; number:2 ; month:02 ; pages:63-67 |
| Links: |
|---|
| DOI / URN: |
10.1007/s10330-010-0009-7 |
|---|
| Katalog-ID: |
SPR009463577 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR009463577 | ||
| 003 | DE-627 | ||
| 005 | 20230519130850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201005s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10330-010-0009-7 |2 doi | |
| 035 | |a (DE-627)SPR009463577 | ||
| 035 | |a (SPR)s10330-010-0009-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.81 |2 bkl | ||
| 100 | 1 | |a Shi, Zhiyong |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The investigation of symptoms burden and treatment status in patients with bone metastasis |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective This survey was a non-intervention study, which aimed to investigate symptom burden and treatment status in cancer patient with bone metastasis, and to make out whether patients received the normative treatment. Methods We designed a questionnaire, the main items of which include patient’s symptom burden, previous and ongoing treatment. We used it to investigate 120 patients from six different medical agencies. We examined the association between symptoms using Spearman’s rank correlation. SPSS software was used to analyze data. Results The data of one hundred one questionnaires were completed and fitted for analysis. The five most prevalent symptoms were fatigue (84.2%), unhappiness (83.2%), pain (77.2%), dry mouth (77.2%) and lack of appetite (73.3%). Three symptom clusters were identified. Cluster 1 included anxiety and unhappiness and accounted for 61.4% in all patients. Cluster 2 included pain, fatigue and constipation and accounted for 39.6% in all patients. Cluster 3 included nausea, vomiting, lack of appetite and accounted for 27.7% in all patients. Cronbach’s alpha coefficient demonstrated high internal reliability in the clusters, with a coefficient ranging from 0.65 to 0.84. The proportion of patients receiving analgesic therapy, bisphosphates therapy, palliative chemotherapy and radiotherapy were 70.3%, 63.4%, 58.4% and 36.6% respectively. Pain in various degree was obviously alleviated (P < 0.01) after analgesic therapy. Among the surveyed patients, 64 patients received bisphosphates therapy, while the administration of zoledronic acid accounted for the most large proportion. The average duration of bisphosphates administration was 5.79 months (SD = 7.43). Patients who received radiotherapy adopted multiple fractions treating mode. Conclusion Symptom burden was common and severe in patients with bone metastasis, which often appeared as symptom cluster, and significantly affected their quality of life (QOL). The normative treatment should be strengthened to manage and control patients’ symptoms and improve their QOL. The analgesic therapy was normative in patients with bone metastasis. Reasons impeding patients to receive bisphosphates were in varieties. More propaganda should be done to generalized bisphosphates therapy for patients with bone metastasis. | ||
| 700 | 1 | |a Qiu, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Shiying |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Chinese-german journal of clinical oncology |d Berlin : Springer, 2002 |g 9(2010), 2 vom: Feb., Seite 63-67 |w (DE-627)39223677X |w (DE-600)2157135-1 |x 1613-9089 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2010 |g number:2 |g month:02 |g pages:63-67 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10330-010-0009-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_121 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_152 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_374 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_647 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_711 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2036 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2050 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2056 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2119 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_2700 | ||
| 912 | |a GBV_ILN_2817 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4277 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4328 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4346 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4392 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4753 | ||
| 936 | b | k | |a 44.81 |q ASE |
| 951 | |a AR | ||
| 952 | |d 9 |j 2010 |e 2 |c 02 |h 63-67 | ||
| author_variant |
z s zs h q hq s y sy |
|---|---|
| matchkey_str |
article:16139089:2010----::hivsiainfyposudnntetetttsnai |
| hierarchy_sort_str |
2010 |
| bklnumber |
44.81 |
| publishDate |
2010 |
| allfields |
10.1007/s10330-010-0009-7 doi (DE-627)SPR009463577 (SPR)s10330-010-0009-7-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.81 bkl Shi, Zhiyong verfasserin aut The investigation of symptoms burden and treatment status in patients with bone metastasis 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective This survey was a non-intervention study, which aimed to investigate symptom burden and treatment status in cancer patient with bone metastasis, and to make out whether patients received the normative treatment. Methods We designed a questionnaire, the main items of which include patient’s symptom burden, previous and ongoing treatment. We used it to investigate 120 patients from six different medical agencies. We examined the association between symptoms using Spearman’s rank correlation. SPSS software was used to analyze data. Results The data of one hundred one questionnaires were completed and fitted for analysis. The five most prevalent symptoms were fatigue (84.2%), unhappiness (83.2%), pain (77.2%), dry mouth (77.2%) and lack of appetite (73.3%). Three symptom clusters were identified. Cluster 1 included anxiety and unhappiness and accounted for 61.4% in all patients. Cluster 2 included pain, fatigue and constipation and accounted for 39.6% in all patients. Cluster 3 included nausea, vomiting, lack of appetite and accounted for 27.7% in all patients. Cronbach’s alpha coefficient demonstrated high internal reliability in the clusters, with a coefficient ranging from 0.65 to 0.84. The proportion of patients receiving analgesic therapy, bisphosphates therapy, palliative chemotherapy and radiotherapy were 70.3%, 63.4%, 58.4% and 36.6% respectively. Pain in various degree was obviously alleviated (P < 0.01) after analgesic therapy. Among the surveyed patients, 64 patients received bisphosphates therapy, while the administration of zoledronic acid accounted for the most large proportion. The average duration of bisphosphates administration was 5.79 months (SD = 7.43). Patients who received radiotherapy adopted multiple fractions treating mode. Conclusion Symptom burden was common and severe in patients with bone metastasis, which often appeared as symptom cluster, and significantly affected their quality of life (QOL). The normative treatment should be strengthened to manage and control patients’ symptoms and improve their QOL. The analgesic therapy was normative in patients with bone metastasis. Reasons impeding patients to receive bisphosphates were in varieties. More propaganda should be done to generalized bisphosphates therapy for patients with bone metastasis. Qiu, Hong verfasserin aut Yu, Shiying verfasserin aut Enthalten in The Chinese-german journal of clinical oncology Berlin : Springer, 2002 9(2010), 2 vom: Feb., Seite 63-67 (DE-627)39223677X (DE-600)2157135-1 1613-9089 nnns volume:9 year:2010 number:2 month:02 pages:63-67 https://dx.doi.org/10.1007/s10330-010-0009-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_121 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_267 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_647 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2036 GBV_ILN_2037 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2119 GBV_ILN_2129 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_2700 GBV_ILN_2817 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4277 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4346 GBV_ILN_4367 GBV_ILN_4392 GBV_ILN_4393 GBV_ILN_4753 44.81 ASE AR 9 2010 2 02 63-67 |
| spelling |
10.1007/s10330-010-0009-7 doi (DE-627)SPR009463577 (SPR)s10330-010-0009-7-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.81 bkl Shi, Zhiyong verfasserin aut The investigation of symptoms burden and treatment status in patients with bone metastasis 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective This survey was a non-intervention study, which aimed to investigate symptom burden and treatment status in cancer patient with bone metastasis, and to make out whether patients received the normative treatment. Methods We designed a questionnaire, the main items of which include patient’s symptom burden, previous and ongoing treatment. We used it to investigate 120 patients from six different medical agencies. We examined the association between symptoms using Spearman’s rank correlation. SPSS software was used to analyze data. Results The data of one hundred one questionnaires were completed and fitted for analysis. The five most prevalent symptoms were fatigue (84.2%), unhappiness (83.2%), pain (77.2%), dry mouth (77.2%) and lack of appetite (73.3%). Three symptom clusters were identified. Cluster 1 included anxiety and unhappiness and accounted for 61.4% in all patients. Cluster 2 included pain, fatigue and constipation and accounted for 39.6% in all patients. Cluster 3 included nausea, vomiting, lack of appetite and accounted for 27.7% in all patients. Cronbach’s alpha coefficient demonstrated high internal reliability in the clusters, with a coefficient ranging from 0.65 to 0.84. The proportion of patients receiving analgesic therapy, bisphosphates therapy, palliative chemotherapy and radiotherapy were 70.3%, 63.4%, 58.4% and 36.6% respectively. Pain in various degree was obviously alleviated (P < 0.01) after analgesic therapy. Among the surveyed patients, 64 patients received bisphosphates therapy, while the administration of zoledronic acid accounted for the most large proportion. The average duration of bisphosphates administration was 5.79 months (SD = 7.43). Patients who received radiotherapy adopted multiple fractions treating mode. Conclusion Symptom burden was common and severe in patients with bone metastasis, which often appeared as symptom cluster, and significantly affected their quality of life (QOL). The normative treatment should be strengthened to manage and control patients’ symptoms and improve their QOL. The analgesic therapy was normative in patients with bone metastasis. Reasons impeding patients to receive bisphosphates were in varieties. More propaganda should be done to generalized bisphosphates therapy for patients with bone metastasis. Qiu, Hong verfasserin aut Yu, Shiying verfasserin aut Enthalten in The Chinese-german journal of clinical oncology Berlin : Springer, 2002 9(2010), 2 vom: Feb., Seite 63-67 (DE-627)39223677X (DE-600)2157135-1 1613-9089 nnns volume:9 year:2010 number:2 month:02 pages:63-67 https://dx.doi.org/10.1007/s10330-010-0009-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_121 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_267 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_647 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2036 GBV_ILN_2037 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2119 GBV_ILN_2129 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_2700 GBV_ILN_2817 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4277 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4346 GBV_ILN_4367 GBV_ILN_4392 GBV_ILN_4393 GBV_ILN_4753 44.81 ASE AR 9 2010 2 02 63-67 |
| allfields_unstemmed |
10.1007/s10330-010-0009-7 doi (DE-627)SPR009463577 (SPR)s10330-010-0009-7-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.81 bkl Shi, Zhiyong verfasserin aut The investigation of symptoms burden and treatment status in patients with bone metastasis 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective This survey was a non-intervention study, which aimed to investigate symptom burden and treatment status in cancer patient with bone metastasis, and to make out whether patients received the normative treatment. Methods We designed a questionnaire, the main items of which include patient’s symptom burden, previous and ongoing treatment. We used it to investigate 120 patients from six different medical agencies. We examined the association between symptoms using Spearman’s rank correlation. SPSS software was used to analyze data. Results The data of one hundred one questionnaires were completed and fitted for analysis. The five most prevalent symptoms were fatigue (84.2%), unhappiness (83.2%), pain (77.2%), dry mouth (77.2%) and lack of appetite (73.3%). Three symptom clusters were identified. Cluster 1 included anxiety and unhappiness and accounted for 61.4% in all patients. Cluster 2 included pain, fatigue and constipation and accounted for 39.6% in all patients. Cluster 3 included nausea, vomiting, lack of appetite and accounted for 27.7% in all patients. Cronbach’s alpha coefficient demonstrated high internal reliability in the clusters, with a coefficient ranging from 0.65 to 0.84. The proportion of patients receiving analgesic therapy, bisphosphates therapy, palliative chemotherapy and radiotherapy were 70.3%, 63.4%, 58.4% and 36.6% respectively. Pain in various degree was obviously alleviated (P < 0.01) after analgesic therapy. Among the surveyed patients, 64 patients received bisphosphates therapy, while the administration of zoledronic acid accounted for the most large proportion. The average duration of bisphosphates administration was 5.79 months (SD = 7.43). Patients who received radiotherapy adopted multiple fractions treating mode. Conclusion Symptom burden was common and severe in patients with bone metastasis, which often appeared as symptom cluster, and significantly affected their quality of life (QOL). The normative treatment should be strengthened to manage and control patients’ symptoms and improve their QOL. The analgesic therapy was normative in patients with bone metastasis. Reasons impeding patients to receive bisphosphates were in varieties. More propaganda should be done to generalized bisphosphates therapy for patients with bone metastasis. Qiu, Hong verfasserin aut Yu, Shiying verfasserin aut Enthalten in The Chinese-german journal of clinical oncology Berlin : Springer, 2002 9(2010), 2 vom: Feb., Seite 63-67 (DE-627)39223677X (DE-600)2157135-1 1613-9089 nnns volume:9 year:2010 number:2 month:02 pages:63-67 https://dx.doi.org/10.1007/s10330-010-0009-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_121 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_267 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_647 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2036 GBV_ILN_2037 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2119 GBV_ILN_2129 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_2700 GBV_ILN_2817 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4277 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4346 GBV_ILN_4367 GBV_ILN_4392 GBV_ILN_4393 GBV_ILN_4753 44.81 ASE AR 9 2010 2 02 63-67 |
| allfieldsGer |
10.1007/s10330-010-0009-7 doi (DE-627)SPR009463577 (SPR)s10330-010-0009-7-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.81 bkl Shi, Zhiyong verfasserin aut The investigation of symptoms burden and treatment status in patients with bone metastasis 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective This survey was a non-intervention study, which aimed to investigate symptom burden and treatment status in cancer patient with bone metastasis, and to make out whether patients received the normative treatment. Methods We designed a questionnaire, the main items of which include patient’s symptom burden, previous and ongoing treatment. We used it to investigate 120 patients from six different medical agencies. We examined the association between symptoms using Spearman’s rank correlation. SPSS software was used to analyze data. Results The data of one hundred one questionnaires were completed and fitted for analysis. The five most prevalent symptoms were fatigue (84.2%), unhappiness (83.2%), pain (77.2%), dry mouth (77.2%) and lack of appetite (73.3%). Three symptom clusters were identified. Cluster 1 included anxiety and unhappiness and accounted for 61.4% in all patients. Cluster 2 included pain, fatigue and constipation and accounted for 39.6% in all patients. Cluster 3 included nausea, vomiting, lack of appetite and accounted for 27.7% in all patients. Cronbach’s alpha coefficient demonstrated high internal reliability in the clusters, with a coefficient ranging from 0.65 to 0.84. The proportion of patients receiving analgesic therapy, bisphosphates therapy, palliative chemotherapy and radiotherapy were 70.3%, 63.4%, 58.4% and 36.6% respectively. Pain in various degree was obviously alleviated (P < 0.01) after analgesic therapy. Among the surveyed patients, 64 patients received bisphosphates therapy, while the administration of zoledronic acid accounted for the most large proportion. The average duration of bisphosphates administration was 5.79 months (SD = 7.43). Patients who received radiotherapy adopted multiple fractions treating mode. Conclusion Symptom burden was common and severe in patients with bone metastasis, which often appeared as symptom cluster, and significantly affected their quality of life (QOL). The normative treatment should be strengthened to manage and control patients’ symptoms and improve their QOL. The analgesic therapy was normative in patients with bone metastasis. Reasons impeding patients to receive bisphosphates were in varieties. More propaganda should be done to generalized bisphosphates therapy for patients with bone metastasis. Qiu, Hong verfasserin aut Yu, Shiying verfasserin aut Enthalten in The Chinese-german journal of clinical oncology Berlin : Springer, 2002 9(2010), 2 vom: Feb., Seite 63-67 (DE-627)39223677X (DE-600)2157135-1 1613-9089 nnns volume:9 year:2010 number:2 month:02 pages:63-67 https://dx.doi.org/10.1007/s10330-010-0009-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_121 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_267 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_647 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2036 GBV_ILN_2037 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2119 GBV_ILN_2129 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_2700 GBV_ILN_2817 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4277 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4346 GBV_ILN_4367 GBV_ILN_4392 GBV_ILN_4393 GBV_ILN_4753 44.81 ASE AR 9 2010 2 02 63-67 |
| allfieldsSound |
10.1007/s10330-010-0009-7 doi (DE-627)SPR009463577 (SPR)s10330-010-0009-7-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE 44.81 bkl Shi, Zhiyong verfasserin aut The investigation of symptoms burden and treatment status in patients with bone metastasis 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective This survey was a non-intervention study, which aimed to investigate symptom burden and treatment status in cancer patient with bone metastasis, and to make out whether patients received the normative treatment. Methods We designed a questionnaire, the main items of which include patient’s symptom burden, previous and ongoing treatment. We used it to investigate 120 patients from six different medical agencies. We examined the association between symptoms using Spearman’s rank correlation. SPSS software was used to analyze data. Results The data of one hundred one questionnaires were completed and fitted for analysis. The five most prevalent symptoms were fatigue (84.2%), unhappiness (83.2%), pain (77.2%), dry mouth (77.2%) and lack of appetite (73.3%). Three symptom clusters were identified. Cluster 1 included anxiety and unhappiness and accounted for 61.4% in all patients. Cluster 2 included pain, fatigue and constipation and accounted for 39.6% in all patients. Cluster 3 included nausea, vomiting, lack of appetite and accounted for 27.7% in all patients. Cronbach’s alpha coefficient demonstrated high internal reliability in the clusters, with a coefficient ranging from 0.65 to 0.84. The proportion of patients receiving analgesic therapy, bisphosphates therapy, palliative chemotherapy and radiotherapy were 70.3%, 63.4%, 58.4% and 36.6% respectively. Pain in various degree was obviously alleviated (P < 0.01) after analgesic therapy. Among the surveyed patients, 64 patients received bisphosphates therapy, while the administration of zoledronic acid accounted for the most large proportion. The average duration of bisphosphates administration was 5.79 months (SD = 7.43). Patients who received radiotherapy adopted multiple fractions treating mode. Conclusion Symptom burden was common and severe in patients with bone metastasis, which often appeared as symptom cluster, and significantly affected their quality of life (QOL). The normative treatment should be strengthened to manage and control patients’ symptoms and improve their QOL. The analgesic therapy was normative in patients with bone metastasis. Reasons impeding patients to receive bisphosphates were in varieties. More propaganda should be done to generalized bisphosphates therapy for patients with bone metastasis. Qiu, Hong verfasserin aut Yu, Shiying verfasserin aut Enthalten in The Chinese-german journal of clinical oncology Berlin : Springer, 2002 9(2010), 2 vom: Feb., Seite 63-67 (DE-627)39223677X (DE-600)2157135-1 1613-9089 nnns volume:9 year:2010 number:2 month:02 pages:63-67 https://dx.doi.org/10.1007/s10330-010-0009-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_121 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_267 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_647 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2036 GBV_ILN_2037 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2119 GBV_ILN_2129 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_2700 GBV_ILN_2817 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4277 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4346 GBV_ILN_4367 GBV_ILN_4392 GBV_ILN_4393 GBV_ILN_4753 44.81 ASE AR 9 2010 2 02 63-67 |
| language |
English |
| source |
Enthalten in The Chinese-german journal of clinical oncology 9(2010), 2 vom: Feb., Seite 63-67 volume:9 year:2010 number:2 month:02 pages:63-67 |
| sourceStr |
Enthalten in The Chinese-german journal of clinical oncology 9(2010), 2 vom: Feb., Seite 63-67 volume:9 year:2010 number:2 month:02 pages:63-67 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
The Chinese-german journal of clinical oncology |
| authorswithroles_txt_mv |
Shi, Zhiyong @@aut@@ Qiu, Hong @@aut@@ Yu, Shiying @@aut@@ |
| publishDateDaySort_date |
2010-02-01T00:00:00Z |
| hierarchy_top_id |
39223677X |
| dewey-sort |
3610 |
| id |
SPR009463577 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009463577</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519130850.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2010 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10330-010-0009-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009463577</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10330-010-0009-7-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.81</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shi, Zhiyong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The investigation of symptoms burden and treatment status in patients with bone metastasis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2010</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective This survey was a non-intervention study, which aimed to investigate symptom burden and treatment status in cancer patient with bone metastasis, and to make out whether patients received the normative treatment. Methods We designed a questionnaire, the main items of which include patient’s symptom burden, previous and ongoing treatment. We used it to investigate 120 patients from six different medical agencies. We examined the association between symptoms using Spearman’s rank correlation. SPSS software was used to analyze data. Results The data of one hundred one questionnaires were completed and fitted for analysis. The five most prevalent symptoms were fatigue (84.2%), unhappiness (83.2%), pain (77.2%), dry mouth (77.2%) and lack of appetite (73.3%). Three symptom clusters were identified. Cluster 1 included anxiety and unhappiness and accounted for 61.4% in all patients. Cluster 2 included pain, fatigue and constipation and accounted for 39.6% in all patients. Cluster 3 included nausea, vomiting, lack of appetite and accounted for 27.7% in all patients. Cronbach’s alpha coefficient demonstrated high internal reliability in the clusters, with a coefficient ranging from 0.65 to 0.84. The proportion of patients receiving analgesic therapy, bisphosphates therapy, palliative chemotherapy and radiotherapy were 70.3%, 63.4%, 58.4% and 36.6% respectively. Pain in various degree was obviously alleviated (P < 0.01) after analgesic therapy. Among the surveyed patients, 64 patients received bisphosphates therapy, while the administration of zoledronic acid accounted for the most large proportion. The average duration of bisphosphates administration was 5.79 months (SD = 7.43). Patients who received radiotherapy adopted multiple fractions treating mode. Conclusion Symptom burden was common and severe in patients with bone metastasis, which often appeared as symptom cluster, and significantly affected their quality of life (QOL). The normative treatment should be strengthened to manage and control patients’ symptoms and improve their QOL. The analgesic therapy was normative in patients with bone metastasis. Reasons impeding patients to receive bisphosphates were in varieties. More propaganda should be done to generalized bisphosphates therapy for patients with bone metastasis.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Qiu, Hong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Shiying</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The Chinese-german journal of clinical oncology</subfield><subfield code="d">Berlin : Springer, 2002</subfield><subfield code="g">9(2010), 2 vom: Feb., Seite 63-67</subfield><subfield code="w">(DE-627)39223677X</subfield><subfield code="w">(DE-600)2157135-1</subfield><subfield code="x">1613-9089</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2010</subfield><subfield code="g">number:2</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:63-67</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10330-010-0009-7</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_121</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_374</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_647</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_711</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2036</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2700</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2817</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4277</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4346</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4392</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4753</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.81</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2010</subfield><subfield code="e">2</subfield><subfield code="c">02</subfield><subfield code="h">63-67</subfield></datafield></record></collection>
|
| author |
Shi, Zhiyong |
| spellingShingle |
Shi, Zhiyong ddc 610 bkl 44.81 The investigation of symptoms burden and treatment status in patients with bone metastasis |
| authorStr |
Shi, Zhiyong |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)39223677X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1613-9089 |
| topic_title |
610 ASE 44.81 bkl The investigation of symptoms burden and treatment status in patients with bone metastasis |
| topic |
ddc 610 bkl 44.81 |
| topic_unstemmed |
ddc 610 bkl 44.81 |
| topic_browse |
ddc 610 bkl 44.81 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
The Chinese-german journal of clinical oncology |
| hierarchy_parent_id |
39223677X |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
The Chinese-german journal of clinical oncology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)39223677X (DE-600)2157135-1 |
| title |
The investigation of symptoms burden and treatment status in patients with bone metastasis |
| ctrlnum |
(DE-627)SPR009463577 (SPR)s10330-010-0009-7-e |
| title_full |
The investigation of symptoms burden and treatment status in patients with bone metastasis |
| author_sort |
Shi, Zhiyong |
| journal |
The Chinese-german journal of clinical oncology |
| journalStr |
The Chinese-german journal of clinical oncology |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2010 |
| contenttype_str_mv |
txt |
| container_start_page |
63 |
| author_browse |
Shi, Zhiyong Qiu, Hong Yu, Shiying |
| container_volume |
9 |
| class |
610 ASE 44.81 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Shi, Zhiyong |
| doi_str_mv |
10.1007/s10330-010-0009-7 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
investigation of symptoms burden and treatment status in patients with bone metastasis |
| title_auth |
The investigation of symptoms burden and treatment status in patients with bone metastasis |
| abstract |
Objective This survey was a non-intervention study, which aimed to investigate symptom burden and treatment status in cancer patient with bone metastasis, and to make out whether patients received the normative treatment. Methods We designed a questionnaire, the main items of which include patient’s symptom burden, previous and ongoing treatment. We used it to investigate 120 patients from six different medical agencies. We examined the association between symptoms using Spearman’s rank correlation. SPSS software was used to analyze data. Results The data of one hundred one questionnaires were completed and fitted for analysis. The five most prevalent symptoms were fatigue (84.2%), unhappiness (83.2%), pain (77.2%), dry mouth (77.2%) and lack of appetite (73.3%). Three symptom clusters were identified. Cluster 1 included anxiety and unhappiness and accounted for 61.4% in all patients. Cluster 2 included pain, fatigue and constipation and accounted for 39.6% in all patients. Cluster 3 included nausea, vomiting, lack of appetite and accounted for 27.7% in all patients. Cronbach’s alpha coefficient demonstrated high internal reliability in the clusters, with a coefficient ranging from 0.65 to 0.84. The proportion of patients receiving analgesic therapy, bisphosphates therapy, palliative chemotherapy and radiotherapy were 70.3%, 63.4%, 58.4% and 36.6% respectively. Pain in various degree was obviously alleviated (P < 0.01) after analgesic therapy. Among the surveyed patients, 64 patients received bisphosphates therapy, while the administration of zoledronic acid accounted for the most large proportion. The average duration of bisphosphates administration was 5.79 months (SD = 7.43). Patients who received radiotherapy adopted multiple fractions treating mode. Conclusion Symptom burden was common and severe in patients with bone metastasis, which often appeared as symptom cluster, and significantly affected their quality of life (QOL). The normative treatment should be strengthened to manage and control patients’ symptoms and improve their QOL. The analgesic therapy was normative in patients with bone metastasis. Reasons impeding patients to receive bisphosphates were in varieties. More propaganda should be done to generalized bisphosphates therapy for patients with bone metastasis. |
| abstractGer |
Objective This survey was a non-intervention study, which aimed to investigate symptom burden and treatment status in cancer patient with bone metastasis, and to make out whether patients received the normative treatment. Methods We designed a questionnaire, the main items of which include patient’s symptom burden, previous and ongoing treatment. We used it to investigate 120 patients from six different medical agencies. We examined the association between symptoms using Spearman’s rank correlation. SPSS software was used to analyze data. Results The data of one hundred one questionnaires were completed and fitted for analysis. The five most prevalent symptoms were fatigue (84.2%), unhappiness (83.2%), pain (77.2%), dry mouth (77.2%) and lack of appetite (73.3%). Three symptom clusters were identified. Cluster 1 included anxiety and unhappiness and accounted for 61.4% in all patients. Cluster 2 included pain, fatigue and constipation and accounted for 39.6% in all patients. Cluster 3 included nausea, vomiting, lack of appetite and accounted for 27.7% in all patients. Cronbach’s alpha coefficient demonstrated high internal reliability in the clusters, with a coefficient ranging from 0.65 to 0.84. The proportion of patients receiving analgesic therapy, bisphosphates therapy, palliative chemotherapy and radiotherapy were 70.3%, 63.4%, 58.4% and 36.6% respectively. Pain in various degree was obviously alleviated (P < 0.01) after analgesic therapy. Among the surveyed patients, 64 patients received bisphosphates therapy, while the administration of zoledronic acid accounted for the most large proportion. The average duration of bisphosphates administration was 5.79 months (SD = 7.43). Patients who received radiotherapy adopted multiple fractions treating mode. Conclusion Symptom burden was common and severe in patients with bone metastasis, which often appeared as symptom cluster, and significantly affected their quality of life (QOL). The normative treatment should be strengthened to manage and control patients’ symptoms and improve their QOL. The analgesic therapy was normative in patients with bone metastasis. Reasons impeding patients to receive bisphosphates were in varieties. More propaganda should be done to generalized bisphosphates therapy for patients with bone metastasis. |
| abstract_unstemmed |
Objective This survey was a non-intervention study, which aimed to investigate symptom burden and treatment status in cancer patient with bone metastasis, and to make out whether patients received the normative treatment. Methods We designed a questionnaire, the main items of which include patient’s symptom burden, previous and ongoing treatment. We used it to investigate 120 patients from six different medical agencies. We examined the association between symptoms using Spearman’s rank correlation. SPSS software was used to analyze data. Results The data of one hundred one questionnaires were completed and fitted for analysis. The five most prevalent symptoms were fatigue (84.2%), unhappiness (83.2%), pain (77.2%), dry mouth (77.2%) and lack of appetite (73.3%). Three symptom clusters were identified. Cluster 1 included anxiety and unhappiness and accounted for 61.4% in all patients. Cluster 2 included pain, fatigue and constipation and accounted for 39.6% in all patients. Cluster 3 included nausea, vomiting, lack of appetite and accounted for 27.7% in all patients. Cronbach’s alpha coefficient demonstrated high internal reliability in the clusters, with a coefficient ranging from 0.65 to 0.84. The proportion of patients receiving analgesic therapy, bisphosphates therapy, palliative chemotherapy and radiotherapy were 70.3%, 63.4%, 58.4% and 36.6% respectively. Pain in various degree was obviously alleviated (P < 0.01) after analgesic therapy. Among the surveyed patients, 64 patients received bisphosphates therapy, while the administration of zoledronic acid accounted for the most large proportion. The average duration of bisphosphates administration was 5.79 months (SD = 7.43). Patients who received radiotherapy adopted multiple fractions treating mode. Conclusion Symptom burden was common and severe in patients with bone metastasis, which often appeared as symptom cluster, and significantly affected their quality of life (QOL). The normative treatment should be strengthened to manage and control patients’ symptoms and improve their QOL. The analgesic therapy was normative in patients with bone metastasis. Reasons impeding patients to receive bisphosphates were in varieties. More propaganda should be done to generalized bisphosphates therapy for patients with bone metastasis. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_121 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_267 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_374 GBV_ILN_602 GBV_ILN_647 GBV_ILN_702 GBV_ILN_711 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2036 GBV_ILN_2037 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2119 GBV_ILN_2129 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2190 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_2700 GBV_ILN_2817 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4277 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4346 GBV_ILN_4367 GBV_ILN_4392 GBV_ILN_4393 GBV_ILN_4753 |
| container_issue |
2 |
| title_short |
The investigation of symptoms burden and treatment status in patients with bone metastasis |
| url |
https://dx.doi.org/10.1007/s10330-010-0009-7 |
| remote_bool |
true |
| author2 |
Qiu, Hong Yu, Shiying |
| author2Str |
Qiu, Hong Yu, Shiying |
| ppnlink |
39223677X |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s10330-010-0009-7 |
| up_date |
2024-07-04T02:10:15.026Z |
| _version_ |
1803612601743048704 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009463577</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519130850.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2010 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10330-010-0009-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009463577</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10330-010-0009-7-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.81</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shi, Zhiyong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The investigation of symptoms burden and treatment status in patients with bone metastasis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2010</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective This survey was a non-intervention study, which aimed to investigate symptom burden and treatment status in cancer patient with bone metastasis, and to make out whether patients received the normative treatment. Methods We designed a questionnaire, the main items of which include patient’s symptom burden, previous and ongoing treatment. We used it to investigate 120 patients from six different medical agencies. We examined the association between symptoms using Spearman’s rank correlation. SPSS software was used to analyze data. Results The data of one hundred one questionnaires were completed and fitted for analysis. The five most prevalent symptoms were fatigue (84.2%), unhappiness (83.2%), pain (77.2%), dry mouth (77.2%) and lack of appetite (73.3%). Three symptom clusters were identified. Cluster 1 included anxiety and unhappiness and accounted for 61.4% in all patients. Cluster 2 included pain, fatigue and constipation and accounted for 39.6% in all patients. Cluster 3 included nausea, vomiting, lack of appetite and accounted for 27.7% in all patients. Cronbach’s alpha coefficient demonstrated high internal reliability in the clusters, with a coefficient ranging from 0.65 to 0.84. The proportion of patients receiving analgesic therapy, bisphosphates therapy, palliative chemotherapy and radiotherapy were 70.3%, 63.4%, 58.4% and 36.6% respectively. Pain in various degree was obviously alleviated (P < 0.01) after analgesic therapy. Among the surveyed patients, 64 patients received bisphosphates therapy, while the administration of zoledronic acid accounted for the most large proportion. The average duration of bisphosphates administration was 5.79 months (SD = 7.43). Patients who received radiotherapy adopted multiple fractions treating mode. Conclusion Symptom burden was common and severe in patients with bone metastasis, which often appeared as symptom cluster, and significantly affected their quality of life (QOL). The normative treatment should be strengthened to manage and control patients’ symptoms and improve their QOL. The analgesic therapy was normative in patients with bone metastasis. Reasons impeding patients to receive bisphosphates were in varieties. More propaganda should be done to generalized bisphosphates therapy for patients with bone metastasis.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Qiu, Hong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yu, Shiying</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The Chinese-german journal of clinical oncology</subfield><subfield code="d">Berlin : Springer, 2002</subfield><subfield code="g">9(2010), 2 vom: Feb., Seite 63-67</subfield><subfield code="w">(DE-627)39223677X</subfield><subfield code="w">(DE-600)2157135-1</subfield><subfield code="x">1613-9089</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2010</subfield><subfield code="g">number:2</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:63-67</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10330-010-0009-7</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_121</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_267</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_374</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_647</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_711</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2036</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2700</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2817</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4277</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4346</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4392</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4753</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.81</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2010</subfield><subfield code="e">2</subfield><subfield code="c">02</subfield><subfield code="h">63-67</subfield></datafield></record></collection>
|
| score |
7.3991356 |